Table 4. Univariate survival analyses (log-rank test) according to clinicopathologic features in NSCLC patients with brain metastases.

Variable	No. of patients	Median overall survival (months)	95% CI (months)	P
Total	275	14.9	13.1 ± 16.7
Sex				0.200
Male	183	14.9	12.7 ± 17.1
Female	92	14.9	10.7 ± 19.1
Age (years)				0.026
≤65	215	16.2	14.3 ± 18.1
>65	60	10.2	7.2 ± 13.1
Smoking status				0.001
Never	136	16.9	13.1 ± 20.8
Ever	139	13.4	10.0 ± 16.8
Histology				0.327
AC	246	14.9	12.9 ± 16.9
NAC	29	17.3	9.0 ± 25.7
Number of BM				0.031
<3	166	17.3	14.1 ± 20.4
≥3	109	13.4	11.0 ± 15.7
Size of BM in diameter				0.022
<3 cm	230	15.7	14.1 ± 17.4
≥3 cm	45	10.0	6.7 ± 13.4
Extracraninal lesions				0.221
No	161	15.4	13.0 ± 17.7
Yes	114	13.9	11.9 ± 15.8
Intracranial symptoms				0.118
Yes	95	13.7	9.2 ± 18.2
No	180	15.3	13.3 ± 17.5
T category				0.024
T0	8	33.6	NA
T1	48	16.5	12.1 ± 21.0
T2	106	15.2	12.3 ± 18.2
T3	25	11.4	9.4 ± 13.4
T4	88	13.7	10.9 ± 16.6
N category				<0.001
N0	80	24.1	14.7 ± 33.4
N1-3	195	13.3	11.2 ± 15.4
Treatment modality				<0.001
Symptomatic treatmenta	57	9.0	5.4 ± 12.7
Systemic treatmentb	218	16.5	14.3 ± 18.8

^aSymptomatic treatment, given to reduce intracranial pressure: mannitol 125 mg twice per day via intravenous drip; ^bSystemic treatment, systemic chemotherapy plus local treatment. AC, adenocarcinoma; NAC, non-adenocarcinoma; BM, brain metastases; NA, not available.